Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities.
Beate Bittner, Wolfgang Richter, Johannes Schmidt. BioDrugs 2018
Times Cited: 104
Times Cited: 104
Times Cited
Times Co-cited
Similarity
Subcutaneous delivery of monoclonal antibodies: How do we get there?
Margarida Viola, Joana Sequeira, Raquel Seiça, Francisco Veiga, João Serra, Ana C Santos, António J Ribeiro. J Control Release 2018
Margarida Viola, Joana Sequeira, Raquel Seiça, Francisco Veiga, João Serra, Ana C Santos, António J Ribeiro. J Control Release 2018
30
Subcutaneous absorption of biotherapeutics: knowns and unknowns.
Wolfgang F Richter, Björn Jacobsen. Drug Metab Dispos 2014
Wolfgang F Richter, Björn Jacobsen. Drug Metab Dispos 2014
19
ENHANZE® drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20
Kenneth W Locke, Daniel C Maneval, Michael J LaBarre. Drug Deliv 2019
Kenneth W Locke, Daniel C Maneval, Michael J LaBarre. Drug Deliv 2019
38
Mechanistic determinants of biotherapeutics absorption following SC administration.
Wolfgang F Richter, Suraj G Bhansali, Marilyn E Morris. AAPS J 2012
Wolfgang F Richter, Suraj G Bhansali, Marilyn E Morris. AAPS J 2012
16
Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration.
Gregory I Frost. Expert Opin Drug Deliv 2007
Gregory I Frost. Expert Opin Drug Deliv 2007
15
Subcutaneous Injection Volume of Biopharmaceuticals-Pushing the Boundaries.
Roman Mathaes, Atanas Koulov, Susanne Joerg, Hanns-Christian Mahler. J Pharm Sci 2016
Roman Mathaes, Atanas Koulov, Susanne Joerg, Hanns-Christian Mahler. J Pharm Sci 2016
23
Accelerating the development of novel technologies and tools for the subcutaneous delivery of biotherapeutics.
David S Collins, Manuel Sánchez-Félix, Advait V Badkar, Randall Mrsny. J Control Release 2020
David S Collins, Manuel Sánchez-Félix, Advait V Badkar, Randall Mrsny. J Control Release 2020
65
Challenges and Opportunities for the Subcutaneous Delivery of Therapeutic Proteins.
Michael R Turner, Sathy V Balu-Iyer. J Pharm Sci 2018
Michael R Turner, Sathy V Balu-Iyer. J Pharm Sci 2018
28
Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study.
X Pivot, J Gligorov, V Müller, G Curigliano, A Knoop, S Verma, V Jenkins, N Scotto, S Osborne, L Fallowfield. Ann Oncol 2014
X Pivot, J Gligorov, V Müller, G Curigliano, A Knoop, S Verma, V Jenkins, N Scotto, S Osborne, L Fallowfield. Ann Oncol 2014
15
Evaluation of the impact of viscosity, injection volume, and injection flow rate on subcutaneous injection tolerance.
Cecile Berteau, Orchidée Filipe-Santos, Tao Wang, Humberto E Rojas, Corinne Granger, Florence Schwarzenbach. Med Devices (Auckl) 2015
Cecile Berteau, Orchidée Filipe-Santos, Tao Wang, Humberto E Rojas, Corinne Granger, Florence Schwarzenbach. Med Devices (Auckl) 2015
26
Challenges in the development of high protein concentration formulations.
Steven J Shire, Zahra Shahrokh, Jun Liu. J Pharm Sci 2004
Steven J Shire, Zahra Shahrokh, Jun Liu. J Pharm Sci 2004
12
Optimizing the Bioavailability of Subcutaneously Administered Biotherapeutics Through Mechanochemical Drivers.
D S Collins, L C Kourtis, N R Thyagarajapuram, R Sirkar, S Kapur, M W Harrison, D J Bryan, G B Jones, J M Wright. Pharm Res 2017
D S Collins, L C Kourtis, N R Thyagarajapuram, R Sirkar, S Kapur, M W Harrison, D J Bryan, G B Jones, J M Wright. Pharm Res 2017
45
Subcutaneous administration of biotherapeutics: current experience in animal models.
Thomas A McDonald, Monica L Zepeda, Michael J Tomlinson, Walter H Bee, Inge A Ivens. Curr Opin Mol Ther 2010
Thomas A McDonald, Monica L Zepeda, Michael J Tomlinson, Walter H Bee, Inge A Ivens. Curr Opin Mol Ther 2010
12
Tolerability of High-Volume Subcutaneous Injections of a Viscous Placebo Buffer: A Randomized, Crossover Study in Healthy Subjects.
Clapton Dias, Bassam Abosaleem, Caroline Crispino, Bing Gao, Adam Shaywitz. AAPS PharmSciTech 2015
Clapton Dias, Bassam Abosaleem, Caroline Crispino, Bing Gao, Adam Shaywitz. AAPS PharmSciTech 2015
37
Subcutaneous delivery of biotherapeutics: challenges at the injection site.
Joana A D Sequeira, Ana C Santos, João Serra, Catarina Estevens, Raquel Seiça, Francisco Veiga, António J Ribeiro. Expert Opin Drug Deliv 2019
Joana A D Sequeira, Ana C Santos, João Serra, Catarina Estevens, Raquel Seiça, Francisco Veiga, António J Ribeiro. Expert Opin Drug Deliv 2019
62
Subcutaneous Injection of Drugs: Literature Review of Factors Influencing Pain Sensation at the Injection Site.
Iris Usach, Rafael Martinez, Teodora Festini, José-Esteban Peris. Adv Ther 2019
Iris Usach, Rafael Martinez, Teodora Festini, José-Esteban Peris. Adv Ther 2019
21
Intravenous versus Subcutaneous Drug Administration. Which Do Patients Prefer? A Systematic Review.
Kelly L Stoner, Helena Harder, Lesley J Fallowfield, Valerie A Jenkins. Patient 2014
Kelly L Stoner, Helena Harder, Lesley J Fallowfield, Valerie A Jenkins. Patient 2014
16
Subcutaneous drug delivery: An evolving enterprise.
Graham B Jones, David S Collins, Michael W Harrison, Nagarajan R Thyagarajapuram, Justin M Wright. Sci Transl Med 2017
Graham B Jones, David S Collins, Michael W Harrison, Nagarajan R Thyagarajapuram, Justin M Wright. Sci Transl Med 2017
30
A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer.
Erwin De Cock, Xavier Pivot, Nik Hauser, Sunil Verma, Persefoni Kritikou, Douglas Millar, Ann Knoop. Cancer Med 2016
Erwin De Cock, Xavier Pivot, Nik Hauser, Sunil Verma, Persefoni Kritikou, Douglas Millar, Ann Knoop. Cancer Med 2016
18
High-concentration protein formulations: How high is high?
Patrick Garidel, Alexander B Kuhn, Lars V Schäfer, Anne R Karow-Zwick, Michaela Blech. Eur J Pharm Biopharm 2017
Patrick Garidel, Alexander B Kuhn, Lars V Schäfer, Anne R Karow-Zwick, Michaela Blech. Eur J Pharm Biopharm 2017
14
Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration.
A Supersaxo, W R Hein, H Steffen. Pharm Res 1990
A Supersaxo, W R Hein, H Steffen. Pharm Res 1990
8
Time Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous Infusion: A Time and Motion Study in Eight Countries.
Erwin De Cock, Persefoni Kritikou, Mariana Sandoval, Sunning Tao, Christof Wiesner, Angelo Michele Carella, Charles Ngoh, Tim Waterboer. PLoS One 2016
Erwin De Cock, Persefoni Kritikou, Mariana Sandoval, Sunning Tao, Christof Wiesner, Angelo Michele Carella, Charles Ngoh, Tim Waterboer. PLoS One 2016
16
Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab).
M Rummel, T M Kim, F Aversa, W Brugger, E Capochiani, C Plenteda, F Re, P Trask, S Osborne, R Smith,[...]. Ann Oncol 2017
M Rummel, T M Kim, F Aversa, W Brugger, E Capochiani, C Plenteda, F Re, P Trask, S Osborne, R Smith,[...]. Ann Oncol 2017
14
Impact of Injection Speed, Volume, and Site on Pain Sensation.
Eric Zijlstra, Johannes Jahnke, Annelie Fischer, Christoph Kapitza, Thomas Forst. J Diabetes Sci Technol 2018
Eric Zijlstra, Johannes Jahnke, Annelie Fischer, Christoph Kapitza, Thomas Forst. J Diabetes Sci Technol 2018
30
A recombinant human enzyme for enhanced interstitial transport of therapeutics.
L H Bookbinder, A Hofer, M F Haller, M L Zepeda, G-A Keller, J E Lim, T S Edgington, H M Shepard, J S Patton, G I Frost. J Control Release 2006
L H Bookbinder, A Hofer, M F Haller, M L Zepeda, G-A Keller, J E Lim, T S Edgington, H M Shepard, J S Patton, G I Frost. J Control Release 2006
8
Comparison of subcutaneous and intravenous administration of trastuzumab: a phase I/Ib trial in healthy male volunteers and patients with HER2-positive breast cancer.
Chris Wynne, Vernon Harvey, Christian Schwabe, Devonie Waaka, Christine McIntyre, Beate Bittner. J Clin Pharmacol 2013
Chris Wynne, Vernon Harvey, Christian Schwabe, Devonie Waaka, Christine McIntyre, Beate Bittner. J Clin Pharmacol 2013
9
Improving the outcomes of biopharmaceutical delivery via the subcutaneous route by understanding the chemical, physical and physiological properties of the subcutaneous injection site.
Hanne M Kinnunen, Randall J Mrsny. J Control Release 2014
Hanne M Kinnunen, Randall J Mrsny. J Control Release 2014
10
Subcutaneous drug delivery and the role of the lymphatics.
Danielle N McLennan, Christopher J H Porter, Susan A Charman. Drug Discov Today Technol 2005
Danielle N McLennan, Christopher J H Porter, Susan A Charman. Drug Discov Today Technol 2005
7
Subcutaneous Trastuzumab for HER2-positive Breast Cancer - Evidence and Practical Experience in 7 German Centers.
C Jackisch, V Müller, P Dall, R Neumeister, T-W Park-Simon, A Ruf-Dördelmann, S Seiler, H Tesch, B Ataseven. Geburtshilfe Frauenheilkd 2015
C Jackisch, V Müller, P Dall, R Neumeister, T-W Park-Simon, A Ruf-Dördelmann, S Seiler, H Tesch, B Ataseven. Geburtshilfe Frauenheilkd 2015
26
Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom.
Simon Rule, Graham P Collins, Kunal Samanta. J Med Econ 2014
Simon Rule, Graham P Collins, Kunal Samanta. J Med Econ 2014
16
Understanding Subcutaneous Tissue Pressure for Engineering Injection Devices for Large-Volume Protein Delivery.
Diane V Doughty, Corbin Z Clawson, William Lambert, J Anand Subramony. J Pharm Sci 2016
Diane V Doughty, Corbin Z Clawson, William Lambert, J Anand Subramony. J Pharm Sci 2016
36
Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma.
Saad Z Usmani, Hareth Nahi, Maria-Victoria Mateos, Niels W C J van de Donk, Ajai Chari, Jonathan L Kaufman, Philippe Moreau, Albert Oriol, Torben Plesner, Lotfi Benboubker,[...]. Blood 2019
Saad Z Usmani, Hareth Nahi, Maria-Victoria Mateos, Niels W C J van de Donk, Ajai Chari, Jonathan L Kaufman, Philippe Moreau, Albert Oriol, Torben Plesner, Lotfi Benboubker,[...]. Blood 2019
12
Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial.
Maria-Victoria Mateos, Hareth Nahi, Wojciech Legiec, Sebastian Grosicki, Vladimir Vorobyev, Ivan Spicka, Vania Hungria, Sibirina Korenkova, Nizar Bahlis, Max Flogegard,[...]. Lancet Haematol 2020
Maria-Victoria Mateos, Hareth Nahi, Wojciech Legiec, Sebastian Grosicki, Vladimir Vorobyev, Ivan Spicka, Vania Hungria, Sibirina Korenkova, Nizar Bahlis, Max Flogegard,[...]. Lancet Haematol 2020
7
The therapeutic monoclonal antibody market.
Dawn M Ecker, Susan Dana Jones, Howard L Levine. MAbs 2015
Dawn M Ecker, Susan Dana Jones, Howard L Levine. MAbs 2015
6
Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study.
Xavier Pivot, Joseph Gligorov, Volkmar Müller, Peter Barrett-Lee, Sunil Verma, Ann Knoop, Giuseppe Curigliano, Vladimir Semiglazov, Guillermo López-Vivanco, Valerie Jenkins,[...]. Lancet Oncol 2013
Xavier Pivot, Joseph Gligorov, Volkmar Müller, Peter Barrett-Lee, Sunil Verma, Ann Knoop, Giuseppe Curigliano, Vladimir Semiglazov, Guillermo López-Vivanco, Valerie Jenkins,[...]. Lancet Oncol 2013
6
Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial.
Andrew Davies, Francesco Merli, Biljana Mihaljević, Santiago Mercadal, Noppadol Siritanaratkul, Philippe Solal-Céligny, Axel Boehnke, Claude Berge, Magali Genevray, Artem Zharkov,[...]. Lancet Haematol 2017
Andrew Davies, Francesco Merli, Biljana Mihaljević, Santiago Mercadal, Noppadol Siritanaratkul, Philippe Solal-Céligny, Axel Boehnke, Claude Berge, Magali Genevray, Artem Zharkov,[...]. Lancet Haematol 2017
8
Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study.
Andrew Davies, Francesco Merli, Biljana Mihaljevic, Noppadol Siritanaratkul, Phillippe Solal-Céligny, Martin Barrett, Claude Berge, Beate Bittner, Axel Boehnke, Christine McIntyre,[...]. Lancet Oncol 2014
Andrew Davies, Francesco Merli, Biljana Mihaljevic, Noppadol Siritanaratkul, Phillippe Solal-Céligny, Martin Barrett, Claude Berge, Beate Bittner, Axel Boehnke, Christine McIntyre,[...]. Lancet Oncol 2014
7
Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer: Final Analysis of the HannaH Phase 3 Randomized Clinical Trial.
Christian Jackisch, Daniil Stroyakovskiy, Xavier Pivot, Jin Seok Ahn, Bohuslav Melichar, Shin-Cheh Chen, Christoph Meyenberg, Nedal Al-Sakaff, Dominik Heinzmann, Roberto Hegg. JAMA Oncol 2019
Christian Jackisch, Daniil Stroyakovskiy, Xavier Pivot, Jin Seok Ahn, Bohuslav Melichar, Shin-Cheh Chen, Christoph Meyenberg, Nedal Al-Sakaff, Dominik Heinzmann, Roberto Hegg. JAMA Oncol 2019
19
Subcutaneous trastuzumab (Herceptin) versus intravenous trastuzumab for the treatment of patients with HER2-positive breast cancer: A time, motion and cost assessment study in a lean operating day care oncology unit.
Wiebren A A Tjalma, Tom Van den Mooter, Tim Mertens, Valerie Bastiaens, Manon T Huizing, Konstantinos Papadimitriou. Eur J Obstet Gynecol Reprod Biol 2018
Wiebren A A Tjalma, Tom Van den Mooter, Tim Mertens, Valerie Bastiaens, Manon T Huizing, Konstantinos Papadimitriou. Eur J Obstet Gynecol Reprod Biol 2018
26
Perspectives on Subcutaneous Route of Administration as an Immunogenicity Risk Factor for Therapeutic Proteins.
Lora Hamuro, Grzegorz Kijanka, Francis Kinderman, Harald Kropshofer, De-Xiu Bu, Monica Zepeda, Vibha Jawa. J Pharm Sci 2017
Lora Hamuro, Grzegorz Kijanka, Francis Kinderman, Harald Kropshofer, De-Xiu Bu, Monica Zepeda, Vibha Jawa. J Pharm Sci 2017
18
Impact of injection speed and volume on perceived pain during subcutaneous injections into the abdomen and thigh: a single-centre, randomized controlled trial.
T Heise, L Nosek, S Dellweg, E Zijlstra, K A Præstmark, J Kildegaard, G Nielsen, T Sparre. Diabetes Obes Metab 2014
T Heise, L Nosek, S Dellweg, E Zijlstra, K A Præstmark, J Kildegaard, G Nielsen, T Sparre. Diabetes Obes Metab 2014
11
Pain assessment of subcutaneous injections.
J T Jørgensen, J Rømsing, M Rasmussen, J Møller-Sonnergaard, L Vang, L Musaeus. Ann Pharmacother 1996
J T Jørgensen, J Rømsing, M Rasmussen, J Møller-Sonnergaard, L Vang, L Musaeus. Ann Pharmacother 1996
10
Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects.
Zhenhua Xu, Qingmin Wang, Yanli Zhuang, Bart Frederick, Hong Yan, Esther Bouman-Thio, Joseph C Marini, Monica Keen, David Snead, Hugh M Davis,[...]. J Clin Pharmacol 2010
Zhenhua Xu, Qingmin Wang, Yanli Zhuang, Bart Frederick, Hong Yan, Esther Bouman-Thio, Joseph C Marini, Monica Keen, David Snead, Hugh M Davis,[...]. J Clin Pharmacol 2010
7
The antibody drug absorption following subcutaneous or intramuscular administration and its mathematical description by coupling physiologically based absorption process with the conventional compartment pharmacokinetic model.
Liang Zhao, Ping Ji, Zhihong Li, Partha Roy, Chandrahas G Sahajwalla. J Clin Pharmacol 2013
Liang Zhao, Ping Ji, Zhihong Li, Partha Roy, Chandrahas G Sahajwalla. J Clin Pharmacol 2013
10
Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase.
O Shpilberg, C Jackisch. Br J Cancer 2013
O Shpilberg, C Jackisch. Br J Cancer 2013
8
Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: implications for needle length recommendations.
Michael A Gibney, Christina H Arce, Karen J Byron, Laurence J Hirsch. Curr Med Res Opin 2010
Michael A Gibney, Christina H Arce, Karen J Byron, Laurence J Hirsch. Curr Med Res Opin 2010
6
Porcine model to evaluate local tissue tolerability associated with subcutaneous delivery of protein.
D W Kang, D A Oh, G Y Fu, J M Anderson, M L Zepeda. J Pharmacol Toxicol Methods 2013
D W Kang, D A Oh, G Y Fu, J M Anderson, M L Zepeda. J Pharmacol Toxicol Methods 2013
33
In vitro model for predicting bioavailability of subcutaneously injected monoclonal antibodies.
Hanne Kinnunen Bown, Catherine Bonn, Stefan Yohe, Daniela Bumbaca Yadav, Thomas W Patapoff, Ann Daugherty, Randall J Mrsny. J Control Release 2018
Hanne Kinnunen Bown, Catherine Bonn, Stefan Yohe, Daniela Bumbaca Yadav, Thomas W Patapoff, Ann Daugherty, Randall J Mrsny. J Control Release 2018
21
Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.